CAS NO: | 126105-11-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | 11-oxo-mogroside V is a natural sweetener that exhibits strong antioxidant activity. It exhibits significant inhibitory effects onreactive oxygen species(O2-,H2O2and*OH) withEC50of 4.79, 16.52, and 146.17 μg/mL, respectively. | ||||||||||||||||
IC50& Target | EC50: 4.79 μg/mL (O2-), 16.52 μg/mL (H2O2), 146.17 μg/mL (*OH)[1] | ||||||||||||||||
体外研究 (In Vitro) | 11-oxo-mogroside V shows a higher scavenging effect on O2- (concentration at which 50% of chemiluminescence intensity is inhibited [EC50]=4.79 μg/mL) and H2O2(EC50=16.52 μg/mL) than those of mogroside V. 11-oxo-mogroside V exhibits a remarkable inhibitory effect on *OH-induced DNA damage with EC50=3.09 μg/mL[1].11-oxo-mogroside V, a natural sweetener, isolated from the fruits ofMomordica grosvenori, exhibits strong inhibitory effect on the primary screening test indicated by the induction of Epstein-Barr virus early antigen (EBV-EA) by a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). 11-oxo-mogroside V exhibits strong inhibitory effect on EBV-EA induction (91.2, 50.9 and 21.3% inhibition at 1000, 500 and 100 mol ratio/TPA concentration, respectively)[2]. | ||||||||||||||||
体内研究 (In Vivo) | In the group treated with DMBA, TPA and 11-oxo-mogroside V, only 26.6 and 53.3% of mice bore papillomas even at 10 and 15 weeks of promotion, respectively, and only 1.0 3.3 and 4.7 papillomas are formed per mouse at 10, 15 and 20 weeks of promotion[2]. | ||||||||||||||||
分子量 | 1285.42 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C60H100O29 | ||||||||||||||||
CAS 号 | 126105-11-1 | ||||||||||||||||
中文名称 | 11-氧-罗汉果苷 V;11-O-罗汉果苷 V | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(77.80 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|